Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941932 | 0.80 | GAA (0.34) | ALDH1A1GAAL3MBTL1 | |
| SCHEMBL2889248 | 0.74 | L3MBTL1 (0.34) | ALDH1A1MAPK1PTK2BHPGDSMN1; SMN2 | |
| SCHEMBL2011332 | 0.73 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL2011333 | 0.73 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3599142 | 0.70 | KCNE1 (0.40) | ALDH1A1MAPK1PTK2BL3MBTL1 | |
| SCHEMBL3599146 | 0.70 | KCNE1 (0.40) | ALDH1A1MAPK1PTK2BL3MBTL1 | |
| SCHEMBL12580760 | 0.69 | ABCB1 (0.42) | — | |
| SCHEMBL2875594 | 0.68 | KCNA5 (0.42) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL20424444 | 0.61 | TSHR (0.52) | ALDH1A1MAPK1PTK2BHPGDMEN1 | |
| SCHEMBL2010205 | 0.61 | KCNA5 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | ALDH1A1 2087/4885MAPK1 2627/4885PTK2B 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.